Congratulation Pat!
biz.yahoo.com
After 3 years of delay Company finally make it in France.
>>the French Ministry of Health has approved AmBisome, a liposomal formulation of amphotericin B, for use in the treatment of patients with systemic fungal (aspergillus or candida) infections who have failed or are intolerant to conventional amphotericin B, as well as for therapy of visceral leishmaniasis after failure of conventional treatment.<<
Is this broad label expansion for AmBisome? Where are first line therapy and FUO indication? Label expansion in EU. Anyway, if Company decided to open/expand subsidiary for middle/east EU (Slovenia, Croatia, Hungary, Poland, Romania...), I am first volunteer for half salary which company pay to France subsidiary employees (for last +12 months). You do not have to rush with approval. I will be loyal to Company. :)
BTW, if you are kicked out (which I hope with all my hart), we still have opening for *leaves picker*. This is excellent job position with great prosperity. We just planted four new trees, and have plan for couple more, so job is secured.
Miljenko
|
